title: Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.
abstract: We describe the striking and unexpected evolution of 10 patients with de novo multiple myeloma treated with novel-agent based induction therapy, who displayed a dissociated evolution characterised by an apparent good response contrasting with the concomitant development of aggressive non-secreting plasmocytomas immediately before, or just after, autologous stem cell transplantation. Patients did not respond to salvage therapies. Eight of them died from progression less than 12 months after diagnosis. This unusual evolution in the era of novel agents warrants further scrutiny.
authors.affiliation: Rheumatology Department, Hôpital du Kremlin Bicetre, 94275 Le Kremlin-Bicêtre Cedex, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Crickx
authors.forename: Sebastian
authors.initials: S
authors.lastname: Wittnebel
authors.forename: Florence
authors.initials: F
authors.lastname: Pasquier
authors.forename: Alina
authors.initials: A
authors.lastname: Danu
authors.forename: Jean-Henri
authors.initials: JH
authors.lastname: Bourhis
authors.forename: Vincent
authors.initials: V
authors.lastname: Ribrag
authors.forename: Francois
authors.initials: F
authors.lastname: Boué
authors.forename: Corinne
authors.initials: C
authors.lastname: Miceli
authors.forename: Xavier
authors.initials: X
authors.lastname: Mariette
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.forename: Stéphane de
authors.initials: Sd
authors.lastname: Botton
authors.forename: David
authors.initials: D
authors.lastname: Ghez
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D016879:Salvage Therapy / Q000379:methods*; D033581:Stem Cell Transplantation
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D007155:Immunologic Factors; D011719:Pyrazines; D000069286:Bortezomib